CYB-003 is under clinical development by Cybin and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive Disorder have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CYB-003’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CYB-003 overview

CYB-003 is under development for the treatment of alcohol use disorder and major depressive disorder. The drug candidate is administered through inhalational route and also as orally dissolving tablet.

Cybin overview

Cybin is a biotechnology company that develops psychedelic drugs targeting psychiatric and neurological disorders. It is investigating PSY001, a psiloCybin drug delivered through a sublingual film to treat major depressive disorder; PSY-003, a deuterated tryptamine drug against therapy resistant psychiatric disorders. The company is also evaluating PSY004 and PSY005 drugs targeting various psychiatric indications. Cybin utilizes its proprietary drug discovery platforms, drug delivery systems, and novel formulation approaches to develop its drugs. The company was funded by Janus Henderson Investors, RA Capital, Kearny Venture Partners, Subversive Capital, and LifeSci Venture Partners. It has an operational presence in Massachusetts, the US. Cybin is headquartered in Toronto, Ontario, Canada.

For a complete picture of CYB-003’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.